Navigation Links
Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
Date:9/5/2007

ANN ARBOR, Mich., Sept. 6 /PRNewswire/ -- Terumo Heart Inc. announced today that it is planning a European Launch Symposium at the European Association of Cardio-Thoracic Surgeons (EACTS) meeting in Geneva, Switzerland on September 17, 2007.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061027/DEF004LOGO

http://www.newscom.com/cgi-bin/prnh/20070227/CLTU043LOGO )

A summary of the European Clinical Trial results for the company's DuraHeart(TM) Left Ventricular Assist System (LVAS) will be presented by Dr. Aly El-Banayosy from the Heart Center Nordrhine-Westaflen, Bad Oeynhausen, Germany. This will be followed by a presentation from Dr. Eric Rose, Professor of Surgery at Columbia University Medical Center in New York, entitled "The Emerging New Era of Mechanical Circulatory Support".

The EACTS meeting will mark the official launch of the DuraHeart LVAS. The device has been on the market in Europe for several months and is experiencing significant interest since achieving a CE Mark earlier in the year.

The DuraHeart LVAS is a 3rd generation circulatory support device with full magnetic levitation, intended to provide cardiac support for patients who are at risk of death due to end-stage left ventricular failure. It is the only approved implantable Left Ventricular Assist System combining a centrifugal pump with magnetic levitation of the impeller, providing exceptional reliability and minimizing the potential for blood damage and thrombus. The DuraHeart System is not available in the United States.

Terumo Heart Inc. is a U.S. subsidiary of Terumo Corporation with headquarters and manufacturing facilities in Ann Arbor, Michigan. The company's focus is the innovation and introduction of products to improve the quality of healthcare for the heart failure patient. Terumo Corporation, located in Tokyo, Japan, is a leading developer, manufacturer and global marketer of a wide array of medical products.

Contact: Mark White, Marketing Manager, Terumo Heart Inc., Ann Arbor, Michigan, USA on (734) 741-6262 or mark.white@terumomedical.com.


'/>"/>
SOURCE Terumo Heart Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
2. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
3. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
4. Treating Heart Disease Risk Factors May Slow Alzheimers Disease Progression
5. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
6. Drug for Treatment of Heart Failure Does Not Improve Survival, Compared to More Widely-used Medication
7. deCODE Announces Positive Topline Results for Phase I Study of DG051 for the Prevention of Heart Attack
8. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
9. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
10. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... bioLytical Laboratories, ein Weltführer bei schnellen Tests für Infektionskrankheiten, hat sein ... eingeführt. Continue Reading ... ... , ... ) bioLytical wurde durch die Clinton Health Access ...
(Date:12/2/2016)... , Dec. 2, 2016   CytoSorbents Corporation ... commercializing its European Union approved CytoSorb ® cytokine ... surgery patients worldwide, announced that Dr. Phillip Chan ... 9th Annual LD Micro Main Event investor conference ... at the Luxe Sunset Boulevard Hotel in ...
(Date:12/2/2016)... LYME, Conn. , Dec. 1, 2016  Today, ... has announced the honor of being selected as winners ... include: Simpson Healthcare Executives Website at the PLATINUM level, ... Conversations Training Module at the GOLD Level, and our ... At Simpson Healthcare Executives, we are excited ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... ... The annual time frame to change Medicare health and prescription drug coverage, ... Currently-enrolled Medicare beneficiaries who are looking to switch from their current plan to a ... changes during this period order for their new policy to go into effect in ...
(Date:12/2/2016)... ... 2016 , ... More than half of American teens report losing their virginity ... with their child about sex related topics, less than 60 percent spoke about deeper ... announce the launch of its second edition of the “Sexual Wellness” campaign, aiming to ...
(Date:12/2/2016)... ... 2016 , ... Sourced from the Isbre Springs beneath the 5,000 year old ... purity of just 6 ppm TDS (Total Dissolved Solids) in addition to its excellent ... in several ShopRite and FoodTown stores in NJ and received rave comments from consumers. ...
(Date:12/2/2016)... ... December 02, 2016 , ... On November 24th, ... families from eight different sites throughout Miami-Dade and Broward counties. This is the ... very hard on Thanksgiving morning by putting together individual meals via assembly lines ...
(Date:11/30/2016)... ... November 30, 2016 , ... Northridge ... in-house dental plan for all patients. Understanding that budget can play a part ... a number of perks, including discounts on many valuable dental treatments. Options for ...
Breaking Medicine News(10 mins):